doi:10.1016/j.obpill.2025.100181 Veronese N, Solmi M, Caruso MG, et al
Both Diabetes and Obesity indications will lose exclusivity, including oral versions At least 1 in 3 of people living with obesity in the world will live in a country with access to off patent semaglutide from 2026 There is ambiguity around semaglutides classification as a generic or biosimilar, with many dependent factors such as the originators regulatory pathway and whether off-patent versions are synthesised or recombinant
Every one of our physicians, based in the US, conducts a thorough assessment of each patient and prescribes medication therapy when suitable
Always consult with a healthcare provider if you have any concerns, and remember to follow the instructions carefully to achieve the best results
These foods work well on GLP-1s because they solve two problems at once
It also makes your body hold onto more salt and activates systems that raise blood pressure